EU marketing authorisation application for Memantine FGK (memantine) withdrawn

Source: European Medicines Agency Area: News The European Medicines Agency (EMA) has been formally notified by FGK Representative Service GmbH of its decision to withdraw its application for centralised marketing authorisation for the medicine Memantine FGK (memantine) prolonged-release hard capsules, intended for use for the treatment of patients with moderate to severe Alzheimer's disease. In its official letter, the company stated that it is withdrawing the application for strategic reasons.
Source: NeLM - Mental Health - Category: Psychiatry Source Type: news